Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
4
×
biotech
boston blog main
boston top stories
deals
4
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
novartis
san francisco blog main
san francisco top stories
abbvie
alzheimer's disease
boulder/denver blog main
boulder/denver top stories
cancer
cancer drugs
clinical trials
cystic fibrosis
detroit blog main
detroit top stories
diagnostics
gilead sciences
indiana blog main
indiana top stories
merck
national
pfizer
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
sanofi
seattle blog main
seattle top stories
startups
texas blog main
What
drug
4
×
acquisitions
biggest
bio
ceo
company
medicines
roundup
acquire
agreed
albert
billion
bourla
brings
build
buy
cancer
cash
cholesterol
company’s
compound
crispr
daniel
deal
debut
despite
dyne’s
family
fda
future
gilead
hardest
hit
hottest
hunters
imports
ipo
maker
maps
measured
Language
unset
unknown
Current search:
amgen
×
drug
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
